Two Novel JAK Inhibitors Show Promise in Ulcerative Colitis Two Novel JAK Inhibitors Show Promise in Ulcerative Colitis

Ritlecitinib and brepocitinib were both more effective than placebo with acceptable safety in a phase 2b study of patients with moderate to severe ulcerative colitis.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news